Tyra Biosciences, Inc.TYRANASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank65
3Y CAGR-45.1%
5Y CAGR-28.1%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-45.1%/yr
Quarterly compound
5Y CAGR
-28.1%/yr
Recent deceleration
Percentile
P65
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
3 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 11.44% |
| Q3 2025 | 4.65% |
| Q2 2025 | 3.73% |
| Q1 2025 | -8.96% |
| Q4 2024 | 28.05% |
| Q3 2024 | 6.72% |
| Q2 2024 | 8.13% |
| Q1 2024 | 3.27% |
| Q4 2023 | 5.65% |
| Q3 2023 | 21.81% |
| Q2 2023 | -1.88% |
| Q1 2023 | -14.98% |
| Q4 2022 | 69.16% |
| Q3 2022 | -19.25% |
| Q2 2022 | -34.84% |
| Q1 2022 | 93.48% |
| Q4 2021 | 132.41% |
| Q3 2021 | 2.40% |
| Q2 2021 | 63.57% |
| Q1 2021 | -8.01% |
| Q4 2020 | 59.36% |
| Q3 2020 | 14.08% |
| Q2 2020 | -11.02% |
| Q1 2020 | 0.00% |